{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:17:44Z","timestamp":1793834264492,"version":"4.6.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ygyno.2020.05.042","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T09:17:38Z","timestamp":1591348658000},"page":"785-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Transcriptomic and immunohistochemical approaches identify HLA-G as a predictive biomarker of gestational choriocarcinoma resistance to monochemotherapy"],"prefix":"10.1016","volume":"158","author":[{"given":"Pierre-Adrien","family":"Bolze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Allias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Touria","family":"Hajri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Patrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Devouassoux-Shisheboran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Massardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Golfier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.05.042_bb0005","series-title":"WHO Classification of Tumours of Female Reproductive Organs, Lyon","first-page":"158","article-title":"Gestational trophoblastic neoplasms","author":"Hui","year":"2014"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.09.083","article-title":"Mortality rate of gestational trophoblastic neoplasia with a FIGO score of \u226513","volume":"214","author":"Bolze","year":"2016","journal-title":"Am J Obstet Gynecol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2016.02.014","article-title":"Postmolar choriocarcinoma: an independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia","volume":"141","author":"Strohl","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl","year":"2010","journal-title":"Lancet."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2020.05.042_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.12615","article-title":"Update on the diagnosis and management of gestational trophoblastic disease","volume":"143","author":"Ngan","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajog.2010.06.072","article-title":"Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia","volume":"204","author":"Lurain","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0035","doi-asserted-by":"crossref","first-page":"643.e1","DOI":"10.1016\/j.ajog.2009.03.011","article-title":"Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity","volume":"200","author":"Chalouhi","year":"2009","journal-title":"Am J Obstet Gynecol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2008.11.003","article-title":"Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia","volume":"112","author":"Growdon","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0045","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ygyno.2014.12.024","article-title":"A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom","volume":"136","author":"Taylor","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0050","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ygyno.2004.11.011","article-title":"Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy","volume":"96","author":"Matsui","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0055","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.2014.57.5332","article-title":"Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause","volume":"33","author":"Savage","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0060","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/IGC.0000000000000892","article-title":"PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes","volume":"27","author":"Bolze","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/PGP.0000000000000305","article-title":"PD-L1 expression in human placentas and gestational trophoblastic diseases","volume":"36","author":"Veras","year":"2017","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0070","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2013","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0075","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jgyn.2015.07.006","article-title":"Elaboration of a national biobank for the study of gestational trophoblastic diseases","volume":"45","author":"Bolze","year":"2016","journal-title":"Journal De Gyn\u00e9cologie Obst\u00e9trique Et Biologie De La Reproduction"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0080","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.2002.07.166","article-title":"Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000","volume":"20","author":"McNeish","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0085","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0090","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nm.3981","article-title":"The emerging role of lncRNAs in cancer","volume":"21","author":"Huarte","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0095","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.yexcr.2016.12.003","article-title":"H19 mediates methotrexate resistance in colorectal cancer through activating Wnt\/\u03b2-catenin pathway","volume":"350","author":"Wu","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0100","doi-asserted-by":"crossref","first-page":"15131","DOI":"10.1002\/jcb.28775","article-title":"Long noncoding RNA H19 promotes chemotherapy resistance in choriocarcinoma cells","volume":"120","author":"Yu","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0105","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1073\/pnas.94.10.5249","article-title":"The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?","volume":"94","author":"Rouas-Freiss","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0110","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1182\/blood-2011-05-352393","article-title":"Soluble HLA-G dampens CD94\/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells","volume":"118","author":"Morandi","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1096\/fj.09-135194","article-title":"ILT2\/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse","volume":"24","author":"Favier","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/00000478-200207000-00010","article-title":"HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis","volume":"26","author":"Singer","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0125","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/PAS.0b013e318058a529","article-title":"Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis","volume":"31","author":"Mao","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1600-0897.2010.00897.x","article-title":"The immunohistochemical analysis of RCAS1, HLA-G, and B7H4-positive macrophages in partial and complete hydatidiform mole in both applied therapeutic surgery and surgery followed by chemotherapy","volume":"65","author":"Basta","year":"2011","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0135","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0198-8859(00)00196-8","article-title":"HLA-G expression in trophoblast cells is independent of embryonic development","volume":"61","author":"Rabreau","year":"2000","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0140","series-title":"XIX World Congress Gestational Trophoblastic Diseases, Amsterdam, The Netherlands","article-title":"Pembrolizumab induces long term complete remission of chemotherapy resistant gestational trophoblastic neoplasia","author":"Seckl","year":"2017"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0145","doi-asserted-by":"crossref","first-page":"359748","DOI":"10.1155\/2014\/359748","article-title":"The dual role of HLA-G in cancer","volume":"2014","author":"Rouas-Freiss","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0150","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1309\/JNCW1QLDFB6AM9WE","article-title":"Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma","volume":"128","author":"Yie","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0155","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1158\/1078-0432.CCR-09-0463","article-title":"Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection","volume":"15","author":"Cai","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0160","doi-asserted-by":"crossref","first-page":"107441","DOI":"10.18632\/oncotarget.22487","article-title":"Predictive value of different proportion of lesion HLA-G expression in colorectal cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0165","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/274584","article-title":"HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas","volume":"2014","author":"Rutten","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2004.09.049","article-title":"HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma","volume":"96","author":"Davidson","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0175","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.humimm.2016.01.002","article-title":"The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients","volume":"77","author":"K\u00f6nig","year":"2016","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4326495","article-title":"Recent advances in our understanding of HLA-G biology: lessons from a wide spectrum of human diseases","volume":"2016","author":"Morandi","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0185","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1096\/fj.13-227264","article-title":"Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue","volume":"27","author":"Deschaseaux","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cellimm.2017.11.008","article-title":"The choriocarcinoma cell line JEG-3 upregulates regulatory T cell phenotypes and modulates pro-inflammatory cytokines through HLA-G","volume":"324","author":"Melsted","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12666","article-title":"Type I interferons modulate methotrexate resistance in gestational trophoblastic neoplasia","volume":"77","author":"Elias","year":"2017","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0200","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0205","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0210","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.placenta.2015.05.017","article-title":"ERBB2 gene amplification increases during the transition of proximal EGFR(+) to distal HLA-G(+) first trimester cell column trophoblasts","volume":"36","author":"Meinhardt","year":"2015","journal-title":"Placenta."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0215","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1006\/gyno.2002.6652","article-title":"The relationship between expression of c-ras, c-erbB-2, nm23, and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole","volume":"85","author":"Yang","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9378(12)91825-6","article-title":"Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease","volume":"170","author":"Cameron","year":"1994","journal-title":"The American Journal of Obstetrics & Gynecology"},{"key":"10.1016\/j.ygyno.2020.05.042_bb0225","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1447-0756.2012.01981.x","article-title":"Immunohistochemical expression of the proliferative marker Ki67 in hydatidiform moles and its diagnostic value in the progression to gestational trophoblastic neoplasia","volume":"39","author":"Hasanzadeh","year":"2012","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0230","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1447-0756.2006.00397.x","article-title":"Correlation of c-erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole","volume":"32","author":"Yazaki-Sun","year":"2006","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2020.05.042_bb0235","first-page":"101","article-title":"c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma","volume":"43","author":"Fulop","year":"1998","journal-title":"J Reprod Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820311276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820311276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:53:59Z","timestamp":1758772439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820311276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0090825820311276"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.042","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptomic and immunohistochemical approaches identify HLA-G as a predictive biomarker of gestational choriocarcinoma resistance to monochemotherapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}